Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0279 | 1 | 1 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0279 | 1 | 1 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0279 | 1 | 1 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.0279 | 1 | 1 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.0279 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0113 | 0.0855 | 1 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.0279 | 1 | 1 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0263 | 0.9145 | 0.8951 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.0279 | 1 | 1 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.0279 | 1 | 1 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.0263 | 0.9145 | 0.8951 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 0.27 uM | In vitro inhibitory activity against Adenosine diphosphate(ADP) induced rabbit platelet aggregation | ChEMBL. | 9873372 |
IC50 (functional) | = 1.8 uM | In vitro inhibitory activity against collagen induced rabbit platelet aggregation | ChEMBL. | 9873372 |
Inhibition (functional) | = 20 % | In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 30 mg/kg (p.o.) | ChEMBL. | 9873372 |
Inhibition (functional) | = 78 % | In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 30 mg/kg (p.o.) | ChEMBL. | 9873372 |
Inhibition (functional) | = 78 % | In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 30 mg/kg (p.o.) | ChEMBL. | 9873372 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.